Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Al-Ola Abdallah"'
Autor:
Danai Dima, Al-Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract The presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes of RRMM patients who were treated with standard-of-care (SOC) ch
Externí odkaz:
https://doaj.org/article/4d4e0e6e0fe64208a7cce810ec77ca4d
Autor:
Alexander Lesokhin, Richard LeBlanc, Meletios A. Dimopoulos, Marcelo Capra, Carmelo Carlo‐Stella, Lionel Karlin, Jean‐Francois Castilloux, Peter Forsberg, Gurdeep Parmar, Axel Tosikyan, Ludek Pour, Vincent Ribrag, Rossella Ribolla, Al‐Ola Abdallah, Nadia Le Roux, Liyan Dong, Helgi van deVelde, Laurent Mayrargue, Lucie Lépine, Sandrine Macé, Philippe Moreau
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10254-10266 (2023)
Abstract Background Given the incurable nature of multiple myeloma (MM), efforts are made to improve the efficacy of anti‐CD38 monoclonal antibodies via combinations with other potentially synergistic therapies. This Phase 1/2 trial (NCT03194867) w
Externí odkaz:
https://doaj.org/article/5e8923e3821746dba211ec639b02c19b
Autor:
Saad Z Usmani, Michał Mielnik, Ja Min Byun, Aránzazu Alonso Alonso, Al-Ola Abdallah, Mamta Garg, Hang Quach, Chang-Ki Min, Wojciech Janowski, Enrique Maria Ocio San Miguel, Katja Weisel, Albert Oriol, Irwindeep Sandhu, Paula Rodríguez-Otero, Karthik Ramasamy, Jacqueline Egger, Danaè Williams, Jie MA, Morrys Kaisermann, Marek Hus
Publikováno v:
HemaSphere, Vol 7, p e069676b (2023)
Externí odkaz:
https://doaj.org/article/94129bab4ed74ee4afcfdca9e98785d9
Autor:
Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, Rajat Bansal, Haitham AbdelHakim, Sarah Bromert, Allison Appenfeller, Batool Abu Ghazal, Anurag Singh, Sunil Abhyankar, Siddhartha Ganguly, Joseph McGuirk, Al-Ola Abdallah, Leyla Shune
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy. Despite the promising outcomes, there were limited apheresis/pro
Externí odkaz:
https://doaj.org/article/2b8971cfcaa84a3c9175b572237e8814
Autor:
Oliver Van Oekelen, Nicole Birrer, William Wesson, Vincent L. Galate, Edward R. Scheffer Cliff, Aaron M. Goodman, Al-Ola Abdallah, Rajshekhar Chakraborty, Vinay Prasad, Ghulam Rehman Mohyuddin
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 11, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/61a6cc8b32914c95ae3ea1eab52fca80
Autor:
Kellen Gil, Saqib Abbasi, Kathan Mehta, Brian McClune, Douglas Sborov, Nausheen Ahmed, Al-Ola Abdallah, Siddhartha Ganguly, Joseph McGuirk, Leyla Shune, Ghulam Rehman Mohyuddin
Publikováno v:
Clinical Hematology International, Vol 4, Iss 1-2, Pp 56-59 (2022)
Externí odkaz:
https://doaj.org/article/f9fd2a5a2a394e85b4b1c6000ab3a13c
Autor:
Aimaz Afrough, Shebli Atrash, Barry Paul, Evguenia Ouchveridze, Nausheen Ahmed, Zahra Mahmoudjafari, Anam Bashir, Omar Alkharabsheh, Hamza Hashmi, Al-Ola Abdallah
Publikováno v:
Cancers, Vol 15, Iss 19, p 4894 (2023)
Daratumumab-based combinations with pomalidomide/dexamethasone (DPd), or bortezomib/dexamethasone (DVd), have shown activity in relapsed/refractory multiple myeloma (RRMM) patients. However, no direct comparisons of safety or efficacy of the two regi
Externí odkaz:
https://doaj.org/article/fd167dad4fea4a3e8f85ce7948b625cd
Autor:
Al‐Ola Abdallah, Ghulam Rehman Mohyuddin, Nausheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Zahra Mahmoudjafari, Joseph McGuirk, Siddhartha Ganguly, Shebli Atrash
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 757-764 (2021)
Abstract Extramedullary disease (EMD) is an aggressive form of multiple myeloma (MM). Confirming the presence of plasma cells outside the bone marrow makes the diagnosis of EMD. There is no clear consensus on the management of EMD in MM, and this ent
Externí odkaz:
https://doaj.org/article/9b6ae2a2d7dc462bb14a482feb0aa1d7
Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy
Autor:
Shebli Atrash, Aytaj Mammadzadeh, Fulei Peng, Omar Alkharabsheh, Aimaz Afrough, Wei Cui, Zahra Mahmoudjafari, Al-Ola Abdallah, Hamza Hashmi
Publikováno v:
Cancers, Vol 15, Iss 11, p 2891 (2023)
Despite advances in treatment, outcomes remain poor for patients with penta-relapsed refractory multiple myeloma (RRMM). In this retrospective analysis, we evaluated the survival outcomes of penta-RRMM patients treated with (BCMA)- directed therapy (
Externí odkaz:
https://doaj.org/article/ed6c591ef6b44c959542aa2783915d6e
Autor:
Nicole Balmaceda, Muhammad Aziz, Viveksandeep Thoguluva Chandrasekar, Brian McClune, Suman Kambhampati, Leyla Shune, Al-Ola Abdallah, Faiz Anwer, Aneela Majeed, Muzaffar Qazilbash, Siddhartha Ganguly, Joseph McGuirk, Ghulam Rehman Mohyuddin
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Patients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments. Methods We performed a systematic review to evaluate the monthly risk of grade III/IV infe
Externí odkaz:
https://doaj.org/article/cb3bb2d95ce64ff995577383bb9c055e